

AD-A142 955

EFFECT OF ADJUVANTS ON RESPONSE TO PNEUMOCOCCAL
POLYSACCHARIDE INJECTED I. (U) NEW YORK UNIV MEDICAL
CENTER NY DEPT OF PATHOLOGY G J THORBECKE ET AL.

1/1


UNCLASSIFIED

01 JUL 84 N00014-83-K-0678

F/G 6/5

NL





MICROCOPY RESOLUTION TEST CHART
NATIONAL BUREAU OF STANDARDS-1963-A

AD-A142 955

SECURITY CLASSIFICATION OF THIS PAGE (When Data Entered)

REPORT DOCUMENTATION PAGE		READ INSTRUCTIONS BEFORE COMPLETING FORM
1. REPORT NUMBER 1	2. GOVT ACCESSION NO.	3. RECIPIENT'S CATALOG NUMBER
4. TITLE (and Subtitle) Effect of Adjuvants on Response to Pneumococcal Polysaccharide Injected Intraperitoneally. Platelet-Derived Immunoregulatory Activity.		5. TYPE OF REPORT & PERIOD COVERED annual report 7/1/83 - 6/30/84
7. AUTHOR(s) G. Jeanette Thorbecke and Zoltan Ovary		6. PERFORMING ORG. REPORT NUMBER
9. PERFORMING ORGANIZATION NAME AND ADDRESS Department of Pathology, New York University Medical Center, 550 First Avenue New York, New York 10016		8. CONTRACT OR GRANT NUMBER(s) N00014-83-K-0678
11. CONTROLLING OFFICE NAME AND ADDRESS Jeannine A. Majde, Ph.D., Scientific Officer, Immunology Code441, Cellular Biosystems Group, Dept. of the Navy, ONR, Arlington, VA 22217		10. PROGRAM ELEMENT, PROJECT, TASK AREA & WORK UNIT NUMBERS NR 666-019
14. MONITORING AGENCY NAME & ADDRESS (if different from Controlling Office)		12. REPORT DATE July 1, 1984
		13. NUMBER OF PAGES 13
		15. SECURITY CLASS. (of this report) Unclassified
		15a. DECLASSIFICATION/DOWNGRADING SCHEDULE
16. DISTRIBUTION STATEMENT (of this Report) Unlimited		
17. DISTRIBUTION STATEMENT (of the abstract entered in Block 20, if different from Report) S JUL 9 1984 A		
18. SUPPLEMENTARY NOTES		
19. KEY WORDS (Continue on reverse side if necessary and identify by block number) pneumococcal polysaccharide, adjuvants, immunoregulation, platelet-derived factor.		
20. ABSTRACT (Continue on reverse side if necessary and identify by block number) The PFC response of SJL and BALB/c mice to sheep erythrocytes as well as to a polysaccharide antigen is enhanced by intravenous injection of 0.05 ml normal mouse or human serum but not by plasma. This is particularly evident in mice which have had an injection of an immunosuppressive agent along with the antigen. The factor responsible for this effect is readily absorbed by spleen cells from normal but not from athymic mice. The presence of proteolytic enzyme inhibitors during clotting prevents the appearance of this factor.		

DD FORM 1 JAN 73 1473

EDITION OF 1 NOV 65 IS OBSOLETE

S/N 0102-LF-014-6601

SECURITY CLASSIFICATION OF THIS PAGE (When Data Entered)

84 07 06 044

DMC FILE COPY

20. ABSTRACT(continued)

in serum. On the other hand, addition of thrombin to isolated platelets causes the secretion of this factor into the supernatant. Thus, a connection between platelets and the immune system is revealed by these findings.

The initial studies on the effect of various adjuvants on the immune response to pneumococcal polysaccharide types 3 and 14 have shown so far that a direct B cell activating agent, such as E. coli endotoxin, causes only a very moderate enhancement of the primary 19S antibody response and not sufficient antibody production to cause protective immunity, and that muramyl dipeptide (MDP) has even less effect, whether administered in an emulsion with the polysaccharide or in soluble form.

Effect Of Adjuvants On Response To Pneumococcal Polysaccharide
Injected Intraperitoneally

Experiments were initiated on the effect of adjuvants on the response to i.p. and subcutaneous (footpad) injected pneumococcal polysaccharide (Pn.ps.). The antibody response was evaluated by plaque forming cells (PFC) in spleen and draining (brachial) lymph node, antibody titers and by resistance to challenge with viable pneumococci of the same strain as the polysaccharide used for immunization.

Three polysaccharides (Pn.ps. 3,14 and 19) were examined for their ability to induce PFC responses, serum antibody and protective immunity in BALB/c and SJL mice after i.p. injection. BALB/c mice responded to Pn.ps. 3 and 14, but not to Pn.ps 19. SJL mice also failed to respond to type 19, and showed lower responses to type 14 than BALB/c mice. Various adjuvants, including B. pertussis, MDP, and LPS were used in attempts to induce responses to Pn.ps. 19, without any results. In contrast, the PFC response to Pn.ps. 3 and 14 was enhanced by i.p. injection of LPS, B. pertussis and 8-mercaptoguanosine, but not by MDP and polyAU, not even when MDP was given together with the polysaccharide in an emulsion.

The response to Pn.ps injected into the footpad was so far not detectable by PFC in the draining lymph node although serum antibody titers were higher than in controls. This is now under further examination.

Whole heat-killed pneumococci types 14 and 19 were also used for the immunization of BALB/c mice. In the case of type 14, they induced better responses than polysaccharide alone, but a response to type 19 was still not obtained. Already on days 4-5 after a single injection of 1.2×10^9 killed whole pneumococci type 14 + LPS i.p., the spleen contained 4,500 - 5,000 PFC.



mission For

100-10711

100-10711

100-10711

100-10711

100-10711

100-10711

100-10711

100-10711

100-10711

100-10711

100-10711

100-10711

100-10711

100-10711

100-10711

100-10711

100-10711

100-10711

84 07 06 044

Platelet-Derived Immunoregulatory Activity

When SJL mice are injected intravenously (iv) with γ -irradiated syngeneic lymphoma (γ -RCS) cells at the same time as sheep erythrocytes (SRBC) a marked suppression of the ensuing plaque forming cell (PFC) response in the spleen is observed [Katz et al., J. Natl. Cancer Inst. 72:125, 1984]. This suppression has been interpreted as due to the strong T cell proliferation [Hayama et al., J. Natl. Cancer Inst. 72:321, 1984], IL-2 [Hayama et al., Cell. Immunol. 79:134, 1983] and IFN- γ [Ponzio et al., J. Natl. Cancer Inst. 72:311, 1984] production induced by γ -RCS both in vivo and in vitro. Cyclophosphamide pre-treatment prevented the induction of this suppression, suggesting that a suppressor T cell-mediated phenomenon might be involved.

Immunoregulation in vivo is sometimes accomplished by the injection of monoclonal antibodies or immune sera. In attempting to apply this approach in the elucidation of the mechanism of γ -RCS induced suppression, we obtained an unexpected immunoregulatory effect with iv injected normal mouse serum (NMS), which had been intended to serve as a control. A further analysis of this phenomenon showed that absorption with normal spleen cells of any mouse strain removed the immunoregulatory factor from NMS, confirming its complete lack of strain specificity. As will be shown below we have further characterized this factor and found that it is non-dialyzable and regularly present in normal mouse and human serum, but not in plasma. This factor counteracts suppression when injected 1 day prior to antigen, frequently enhancing the response to SRBC above control levels, and is present in the supernatant of clotted mouse or human platelets as well as in human platelet lysates.

As shown in Table 1, injection of γ -irradiated RCS simultaneously with SRBC into SJL mice caused profound suppression of the PFC response in the spleen measured 4 days later, as described before. This effect was completely abolished by iv injection of 0.2 ml of a 1:4 dilution of NMS. The two experiments in Table 1 represent typical experiments, one in which the response was brought back to the control level by injection of NMS (Expt. 1) and one in which the NMS caused the response to become higher than in the control mice injected with SRBC alone (Expt. 2). Both syngeneic and allogeneic NMS caused the effect, and serum from 9-months-old had the same effect as serum from 2-months-old SJL mice. Absorption with unrelated (A/J mouse) spleen cells removed the activity from the NMS, while absorption with nu/nu (BALB/c) spleen cells did not.

The results in Table 2 confirm these findings and show that the same phenomenon is observed in BALB/c mice using BALB/c NMS. Again, absorption with BALB/c spleen removed the nonspecific enhancing activity, but absorption with nu/nu spleen cells did not. Although the degree of suppression obtained in BALB/c mice, either with γ -RCS (not shown) or with normal LN cells, was only moderate ($\sim 30\%$), both the suppression and the reversal to normal or above normal responses after NMS injection were statistically significant. Even serum obtained from a single mouse, clotted, spun, and reinjected into the same mouse caused the phenomenon of enhancement (Expt. 1, Table 2: autologous serum).

The results in Table 3 show that normal human serum (NHS) also had the immunoregulatory effect in the response of mice to SRBC. In two experiments (Expts. 1 and 2) the response was much higher than in controls not injected with serum or γ -RCS, but in Expt. 3 the response only went back to the control level, overcoming the γ -RCS induced suppression. Absorption of the NHS with mouse spleen or cells from a cytotoxic T cell line reduced or abolished the "contrasuppressive" effect of the NHS. The results in Table 3 suggest, in addition, that the effect is due to a non-dialyzable, heat-resistant factor.

It was of interest to determine whether NHS would also affect the response to other antigens. We, therefore, performed an experiment in SJL mice with $10\ \mu\text{g}$ TNP-Ficoll, to see the effect on a relatively thymus-independent response. The response was not much affected by injection of γ -RCS simultaneously with antigen, as shown previously, but it went from $43,650 \pm 1.05$ to $93,100 \pm 1.1$, when $0.05\ \text{ml}$ NHS was injected iv on the day before antigen (Table 4).

It has been reported that human C5a (anaphylatoxin) may cause an enhancement of the immune response in mouse or in human cells *in vitro* and in mice *in vivo* [11]. Since clotting of blood can lead to activation of the C system, it seemed important to determine whether C5 deficient NMS could also cause the effect. Mice with haplotype k in the H-2S region are known to be deficient in C4 and mice of A strain background have low C5 levels. We, therefore, examined NMS from A.TL mice in A.TL and in A.TFR5 mice. A significant enhancement of the response was obtained in both these C4 and C5 deficient strains, no different from that observed in A.TFR3 and in SJL mice. It was, therefore, concluded that deficiency of these C factors did not much affect this phenomenon.

Another approach to the identification of the factor causing this effect was by use of proteolytic enzyme inhibitors. Addition of soybean trypsin inhibitor (10 μ g/ml) or of tranexamic acid (50 μ M) prior to clotting of blood resulted in NMS devoid of the effect *in vivo* (Fig. 1). Similarly 25 μ M amino-n-caproic acid (EACA) added to blood prior to clotting prevented the appearance of the factor in NMS, while addition of EACA to serum after clotting had no effect (Fig. 2). Plasma failed to affect the immune response *in vivo*, and, more significantly, clotting of plasma produced NMS which also lacked the effect (Figs. 1 and 2). The results in Fig. 1 show, in addition, that the effect of NMS can be seen in the absence of a suppressor cell inducing agent, since the mice in that experiment did not receive any γ -RCS injection.

In view of the lack of effect of NMS prepared from plasma in the absence of cells (Fig. 2) the results suggested that the factor was somehow generated from peripheral blood cells during clotting. Although interaction between B cells and plasminogen have been described [Maillard and Favreau, 1981], the first cells we turned our attention to were the platelets. The results in Fig. 2 show that the supernate from platelets, which had been spun down from lymphocyte and erythrocyte-depleted whole mouse blood and which were then allowed to clot by addition of thrombin (1 U per ml), significantly reversed suppression induced by γ -RCS (Fig. 3). The results in Table 6 demonstrate that similar results were obtained with releasate from human platelets incubated with thrombin. The releasate greatly enhanced the response to SRBC (Expt. 1), at least as much as was observed with serum.

TABLE 1

ANTIBODY PRODUCTION ENHANCING AND/OR SUPPRESSION REVERSING EFFECT OF NORMAL MOUSE SERUM IN SJL

INJECTED IV ON			EXPT. 1		EXPT. 2	
DAY 0 SRBC (10 ⁷)	DAY 0 γ-RCS (2x10 ⁷)	DAY -1 NMS	PFC / SPLEEN	PFC / SPLEEN	PFC / SPLEEN	PFC / SPLEEN
+	-	-	11,700 × 1.2 ^{*0}	8,100 × 1.1		
+	+	-	2,300 × 1.4 [*]	1,100 × 1.1		
+	+	OLD SJL(UNABS.)	11,500 × 1.2 ⁰	N.D.		
+	+	YOUNG SJL(UNABS.)	10,500 × 1.1			
+	+	B10 X 9R(UNABS.)	N.D.	28,200 × 1.1		
+	+	OLD SJL(ABS. WITH A SPLEEN)	4,700 × 1.4 [*]	N.D.		
+	+	B10 X 9R(ABS. WITH A SPLEEN)	N.D.	1,100 × 1.1		
+	+	B10 X 9R(ABS. WITH NUDE BALB/C SPLEEN)	N.D.	34,700 × 1.1		

RESULTS ARE EXPRESSED AS GEOMETRIC MEAN × SE (N=5) OF PFC PER SPLEEN
 ASSAYED 4 DAYS AFTER IV INJECTION OF SRBC.

* N.S.

0 P<.01.

TABLE 2

ANTIBODY PRODUCTION ENHANCING AND/OR SUPPRESSION REVERSING EFFECT OF NORMAL MOUSE SERUM IN BALB/c MICE[#]

INJECTED IV *		EXPT. 1		EXPT. 2	
DAY 0	DAY -1	PFC / SPLEEN		PFC / SPLEEN	
SRBC	SJL CELLS	BALB/c SERUM			
+	-	-		15,800 \pm 1.1	
+	+	-		10,700 \pm 1.1 ⁰ **	
+	+	UNABSORBED (SYNGENEIC)		39,800 \pm 1.1 **	
+	+	ABS. WITH BALB/c SPLEEN		11,500 \pm 1.1 ⁰	
+	+	ABS. WITH NUDE BALB/c SPLEEN		40,700 \pm 1.1	
+	+	UNABSORBED (AUTOLOGOUS)		44,700 \pm 1.1	
				N.D.	

* NORMAL SJL LYMPH NODE CELLS (2×10^7) INJECTED IV TOGETHER WITH SRBC (5×10^6 , EXPT. 1; 10^7 , EXPT. 2).** $P < .0001$.

0 AND 0 N.S.

+ $P < .002$.# RESULTS ARE EXPRESSED AS GEOMETRIC MEAN \pm SE (N=5) OF PFC PER SPLEEN ASSAYED 4 DAYS AFTER IV INJECTION OF SRBC.

TABLE 3

EFFECT OF HUMAN SERUM ON THE ANTI-SRBC RESPONSE OF SJL MICE

Injected iv					Expt. 1 PFC/Sp1	Expt. 2 PFC/Sp1	Expt. 3 PFC/Sp1
Day 0	Day 0	Day -1					
SRBC (10 ⁷)	γ-RCS (2x10 ⁷)	Serum (50 μl)					
+	-	-					
+	+	-					
			Human (NHS)				
+	+	Fresh					
+	+	Absorbed**					
+	+	Heated(30 min. 56°C)					
+	+	Dialyzed					
			Mouse (NMS)				
+	+	Fresh					

Results are expressed as geometric mean \times SE (n=5) of PFC per spleen assayed 4 days after

iv injection of SRBC.

** Absorbed at 4°C 1x (Expt. 1) or 2x (Expt. 2) with mouse spleen (10⁸ cells/0.5 ml of 1:2 dil. NHS) or with CTL-All (murine cytotoxic T cell line; Expt. 3: 3.5 x 10⁷ cells/0.5 ml of 1:2 dil. NHS).

TABLE 4

EFFECT OF NORMAL MOUSE SERUM ON IMMUNE RESPONSE TO TNP-CONJUGATES IN SJL MICE

Injected i.v. on			Geom. Mean Anti-TNP PFC \times SE per Spleen in Response to
Day 0	Day 0	Day -1	
Ag	γ -RCS (2×10^7)	(50 μ l)	TNP-Ficoll
+	-	-	43,652 \times 1.05
+	+	-	46,344 \times 1.05
+	+	Human Serum	93,110 \times 1.10

TABLE 5

PRESENCE OF ANTIBODY RESPONSE ENHANCING FACTOR IN C5 DEFICIENT MICE

Injected i.v. on			Geom. Mean. \bar{x} SE of PFC/Spleen in Mice of Strain			
Day 0	Day 0	Day -1	A. TFR3	A. TFR5	A. TL	SJL
SRBC	γ -RCS	A. TL NMS	(ffffsd)	(ffkkd)	(skkkd)	(sssss)
(10^7)	(2×10^7)	(50 μ l)				
+	-	-	7,250 \bar{x} 1.1	6,900 \bar{x} 1.1	6,150 \bar{x} 1.2	3,000 \bar{x} 1.1
+	+	-	1,950 \bar{x} 1.1	3,250 \bar{x} 1.1		730 \bar{x} 1.6
+	+	+	30,200 \bar{x} 1.1	22,900 \bar{x} 1.1	19,500 \bar{x} 1.2	9,950 \bar{x} 1.5

* No γ -RCS injected in this experiment.
 n = 4-5.


TABLE 6
 ENHANCEMENT BY HUMAN SERUM AND ISOLATED PLATELET RELEASATE OF ANTIBODY PRODUCTION IN SJL MICE**

Injected iv		Day -1		Expt. 1		Expt. 2	
Day 0	Day 0	Day -1		PFC/Sp1		PFC/Sp1	
SRBC (10 ⁷)	γ -RCS (2x10 ⁷)	(50 μ l)					
+	-	-		9,100 $\times \div$ 1.0		7,950 $\times \div$ 1.1	
+	+	-		1,500 $\times \div$ 1.2		1,100 $\times \div$ 1.3	
+	+	NHS					
+	+	NHP				4,000 $\times \div$ 1.5	
+	+	Platelet Lysate/Sup.		27,550 $\times \div$ 1.1		18,600 $\times \div$ 1.1	
+	+	Thrombin [#]				3,600 $\times \div$ 1.3	

* Human platelet releasate from thrombin incubated platelets (approx. 2×10^8 /ml);
 0.2 ml injected per mouse.

Amount of thrombin used was the same as that added to platelets to induce clumping (1 U/ml).

** Results are expressed as geometric mean $\times \div$ SE (n=5) of PFC per spleen assayed 4 days after
 iv injection of SRBC.



Legend for Figures:

Fig. 1. Effect of proteolytic enzyme inhibitors on appearance of antibody enhancing factor in serum during clotting of blood:

Splenic PFC response 4 days after iv injection of 10^7 SRBC (without γ -RCS) in SJL mice, who were also injected iv, 1 day before antigen, with 0.05 ml of normal mouse serum (NMS) which had been produced by clotting of whole blood in the presence of tranexamic acid (TXA, 50 μ M) or of soybean trypsin inhibitor (SBTI, 10 μ g/ml), or with plasma produced from heparinized blood. Results are expressed as % (\bar{x} SE) of control ($n = 5$) and the total PFC per spleen in the control group is indicated in the bar.




Fig. 2. Clotting in the presence of cells is needed for appearance of antibody enhancing factor in serum:

Splenic PFC response 4 days after iv injection of 10^7 SRBC and 2×10^7 γ -RCS in SJL mice, who were also injected iv, 1 day before antigen, with 0.05 ml of normal mouse serum (NMS), normal mouse plasma (NMP), NMS prepared after centrifugation of citrated blood by addition of Ca^{++} (NMS from NMP), or NMS to which EACA ($25 \mu\text{M}$) was added either before or after clotting. The response of mice injected with 10^7 SRBC without γ -RCS is also represented (None, no γ -RCS). Results are expressed as % (\times SE) of control ($n = 4-5$) and the total PFC per spleen in the control group is indicated in the bar.




Fig. 3. Effect of platelet product on the immune response:

Splenic PFC response 4 days after iv injection of 10^7 SRBC and 2×10^7 γ -RCS in SJL mice, also injected iv, 1 day before antigen, with 0.05 ml of thrombin containing clotted platelet supernate, normal mouse serum (NMS) or thrombin alone. Results are expressed as % (\times SE) of control ($n = 5$) and the total PFC per spleen in the control group is indicated in the bar.

DISTRIBUTION LIST

Immunological Defense Program

Annual, Final and Technical Reports (one copy each except as noted)

Dr. John D. Clements
Department of Microbiology
and Immunology
Tulane University Medical Center
1430 Tulane Avenue
New Orleans, LA 70112

Dr. Francis A. Ennis
Department of Medicine
University of Massachusetts
Medical School
55 Lake Avenue
Worcester, MA 01605

Dr. Edward A. Havell
Trudeau Institute
P.O. Box 59
Saranac Lake, NY 12983

Dr. Fred D. Finkelman
Department of Medicine
Uniformed Services University
of the Health Sciences
4301 Jones Bridge Road
Bethesda, MD 20814

Dr. Arthur G. Johnson
Department of Medical
Microbiology and Immunology
University of Minnesota
School of Medicine
2205 East 5th Street
Duluth, MN 55812

Dr. Philip Lake
Immunologic Oncology Division
Lombardy Cancer Center
Georgetown University

Dr. Hillel B. Levine
Naval Biosciences Laboratory
Naval Supply Center
Oakland, CA 94625

Dr. Janice Longstreth
Director of Immunology/Virology
Borrison Laboratories, Inc.
5050 Beech Place
Temple Hills, MD 20748

Dr. Ernest D. Marquez
Department of Microbiology
The Milton S. Hershey Medical Ctr.
Pennsylvania State University
Hershey, PA 170033

Dr. James J. Mond
Department of Medicine
Uniformed Services University
of the Health Sciences
4301 Jones Bridge Road
Bethesda, MD 20814

Dr. Page S. Morahan
Department of Microbiology
Medical College of Pennsylvania
3300 Henry Avenue
Philadelphia, PA 19129

Zoltan Ovary, M.D.
Department of Pathology
New York University
School of Medicine
550 First Avenue
New York, NY 10016

Dr. Donna G. Sieckmann
Infectious Diseases Program Center
Naval Medical Research Institute
National Naval Medical Center
Bethesda, MD 20814

Dr. David A. Stevens
Department of Medicine
Santa Clara Valley Medical Center
Stanford University
751 S. Bascom Avenue
San Jose, CA 95128

Dr. Phyllis R. Struass
Department of Biology
Northeastern University
360 Huntington Avenue
Boston, MA 02115

Dr. Alvin L. Winters
Department of Microbiology
University of Alabama
University, AL 35486

Dr. Lyn Yaffe
Research Support Center
Naval Medical Research Institute
National Naval Medical Center
Bethesda, MD 20814

Annual, Final and Technical Reports (con't)

Dr. Jeannine A. Majde, Code 441CB
Office of Naval Research
800 N. Quincy Street
Arlington, VA 22217

Defense Technical Information Center (2 copies)
Building 5, Cameron Station
Alexandria, VA 22314

Annual and Final Reports Only (one copy each)

Scientific Library
Naval Biosciences Laboratory
Naval Supply Center
Oakland, CA 94625

Commanding Officer
Naval Medical Research & Development Command
National Naval Medical Center
Bethesda, MD 20814

Director
Infectious Disease Program Center
Naval Medical Research Institute
National Naval Medical Center
Bethesda, MD 20814

Commander
Chemical and Biological Sciences Division
Army Research Office
Research Triangle Park, NC 27709

Commander
U.S. Army Research and Development Command
Attn: SGRD-PLA
Fort Detrick
Frederick, MD 21701

Commander
USAMRIID
Fort Detrick
Frederick, MD 21701

Commander
Air Force Office of Scientific Research
Bolling Air Force Base
Washington, DC 20332

Administrative Contracting Officer
Office of Naval Research Residency
(address varies - obtain from Business Office)

Final and Technical Reports Only

Director, Naval Research Laboratory (6 copies)
Attn: Code 2627
Washington, DC 20375

END

FILMED

8

74

DTIC